Summary
AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the overall survival of patients in a late-stage trial. The company was testing the drug,
Source: Reuters on MSN.com
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
